Human patients infected
Conditions
Interventions
Will be included 50 patients in the treatment group and 50 in the placebo group with swab of the anterior nostrils positive for Methicillin-resistant Staphylococcus aureus. These patients suffer colle
Drug
D02.065.884.725.755.800
Sponsors
Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Eligibility
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: Patients admitted in the Hospital das Clinicas, Ribeirão Preto Medical School, University of Sao Paulo; age over 18 years; isolation of methicillin-resistant Staphylococcus aureus.
Exclusion criteria
Exclusion criteria: Volunteers carry cystic fibrosis; patients with chronic osteomyelitis; carry infection related to foreign body; topic pregnancy with a live fetus; negative nasal swab for methicillin-resistant Staphylococcus aureus.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference between the number of patients decolonized by Methicillin-resistant Staphylococcus aureus after decolonization therapy in the experimental group with silver sulfadiazine and placebo group. The evaluation of nasal decolonization be performed by culturing for MRSA nasal swabs. | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference between the number of patients infected by Methicillin-resistant Staphylococcus aureus after decolonization therapy in the experimental group with silver sulfadiazine and placebo group. The evaluation of the incidence of infection will be performed by the Hospital Infection Control Committee. | — |
Countries
Brazil
Contacts
Public ContactLécio Ferreira
Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Outcome results
None listed